|display ongoing studies|
||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results|
COVID 19 hospitalized meta-analysis
|ACTT-2 (Kalil), 2020|
|RCT||baricitinib plus remdesivir||remdesivir||COVID 19 hospitalized||low||515/518||conclusif|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).